Cohance Lifesciences Ltd Share Price

Cohance Lifesciences Reports Q1 Loss as Revenue Declines

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628

🚨 Promoter pledging is something I always check before looking at a stock.

A few mid & smallcap stocks currently have a very high portion of promoter shares pledged. 100% of promoter holding pledged: • Afcons Infra • Bajaj Hindusthan • Indo Borax • Mphasis • Thyrocare Technologies And some others are also above 90%: • Orient Green – 99.99% • Steel Exchange – 99.95% • Jayaswal Neco – 99.87% • A2Z Infra – 99.68% • Gokaldas Exports – 96.28% • Vishnu Prakash – 95.25% • Cohance Life – 94.56% • B.L. Kashyap – 94.44% High promoter pledging doesn't automatically mean the business is bad. But it's definitely something worth checking, especially when the stock starts falling. If lenders ask for more margin, pledged shares can become a problem. Before investing, check why the shares were pledged, company debt and recent FII/DII holding changes.

Cohance Lifesciences shares are likely to remain in focus on August 6 after the company received five observations from the US Food and Drug Administration (USFDA) following an inspection of its Hyderabad manufacturing facility. The USFDA concluded its inspection of the company's Pashamylaram facility in Hyderabad, conducted between July 27 and August 5, 2026. At the end of the inspection, the regulator issued a Form 483 with five observations. The company clarified that none of the observations are related to data integrity. Cohance Lifesciences said it is evaluating the observations and will submit a comprehensive response, along with corrective and preventive actions (CAPAs), to the USFDA within the prescribed timeline. For the June quarter, the company's revenue from operations declined 23.1% year-on-year (YoY) to ₹422.26 crore from ₹549.31 crore in the corresponding quarter last year. It also reported a net loss of ₹24.12 crore, compared with a net profit of ₹48.88 crore in the year-ago period. In the previous trading session, Cohance Lifesciences shares settled at ₹428.95, up ₹3.75, or 0.88%. The stock touched a 52-week high of ₹1,038 on September 8, 2025, and a 52-week low of ₹267.85 on March 9, 2026. It is currently trading 58.68% below its 52-week high and 60.15% above its 52-week low.

Pre Market Report & Global Cues | 06 August, 2026

Global markets are giving mixed signals today. US markets paused after four straight days of gains. Dow managed to close higher, while the S&P 500 and Nasdaq ended slightly lower after giving up their early gains. Asian markets are mixed as well. 🟢 Singapore, China and Indonesia are trading higher. 🔴 Japan, Hong Kong, Taiwan and South Korea are in the red. Even with mixed global markets, Gift Nifty is indicating around a 70-point gap-up, suggesting a positive start for Nifty. Brent crude is holding near $79.9 a barrel, while the rupee strengthened to around 95.1 against the US dollar yesterday. Another positive for the market is that Indian bond yields moved lower after the RBI kept interest rates unchanged. Lower crude prices also helped improve sentiment. Stocks to watch today: ✧ Infosys – Expanded its AI partnership with Metsä Group. ✧ Gland Pharma – Signed a long-term manufacturing agreement with Neuland Laboratories. ✧ LIC – OFS continues today. ✧ Wipro – Launched a new enterprise resilience solution. ✧ Cohance Lifesciences – Received 5 USFDA Form 483 observations. CESC – Raised funds through non-convertible debentures. Today's View: The setup is slightly positive, but global cues are still mixed. After yesterday's session, the key will be whether Nifty can move above the recent range or continue to trade sideways.

COHANCE LIFESCIENCES: CO RECEIVED A FORM FDA 483 CONTAINING FIVE OBSERVATIONS FOR HYDERABAD FACILITY